Loading
NASDAQHealthcareBiotechnology
Latest quote
$24.28
−$0.29 · -1.18%
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Previous close
$24.28
−$0.29 · -1.18%
Regular session · ET · Market data may be delayed.
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Day range
Current $24.28
52-week range
Current $24.28
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
53
Mixed
Risk
52
Elevated Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Day range
Current $24.28
52-week range
Current $24.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 276.98M USD | 178.96M USD | 170.28M USD | 185.31M USD | 154.34M USD |
| Cost of goods sold | 71.36M USD | 72.08M USD | 75.55M USD | 57.91M USD | 49.3M USD |
| Gross profit | 205.62M USD | 106.88M USD | 94.72M USD | 127.4M USD | 105.04M USD |
| Research and development | 93.77M USD | 102.95M USD | 122.12M USD | 141.76M USD | 142.34M USD |
| Selling, general, and administrative | 167.27M USD | 157.57M USD | 172.51M USD | 184.13M USD | 169.97M USD |
| Operating expenses | 262.74M USD | 269.43M USD | 321.76M USD | 327.59M USD | 314.01M USD |
| Interest income | 9.44M USD | 14.53M USD | 15.53M USD | 4.06M USD | 1.67M USD |
| Interest expense | 11.78M USD | 11.58M USD | 13.8M USD | 4.24M USD | — |
| Depreciation and amortization | 17.83M USD | 19.26M USD | 22.23M USD | 20.92M USD | 13.95M USD |
| Operating income | −57.12M USD | −162.55M USD | −227.04M USD | −200.19M USD | −208.97M USD |
| Net income | −59.5M USD | −159.49M USD | −225.25M USD | −200.19M USD | −207.28M USD |
Company facts updated Sep 7, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI109.53M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM97.1M0.12%80.51B USD0.19%$296.01+0.28%
ARK Genomic Revolution ETFARKG45.93M2.29%1.56B USD0.75%$47.14-0.13%
Vanguard Morningstar Small-Cap ETFVB39.49M0.02%183.4B USD0.03%$300.01+0.05%
iShares Russell 2000 Growth ETFIWO35.14M0.24%14.7B USD0.24%$377.54+0.12%
Vanguard Extended Market ETFVXF32.1M0.03%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB28.64M0.26%10.73B USD0.44%$211.92-0.88%
Vanguard Morningstar Small-Cap Growth ETFVBK22.8M0.05%43.8B USD0.05%$349.44+0.01%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Morningstar Small-Cap Growth ETFVBKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
